Treatment with statins after acute myocardial infarction in patients ≥80 years: Underuse despite general acceptance of drug therapy for secondary prevention

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 4, 2006, Pages 261-267

  Kvan, Elena ^a   Pettersen, Kjell I ^b   Landmark, Knud ^a   Reikvam, Åsmund ^a   Waage, K ^c   Vagan A M ^d   Hovland, A ^e   Anker, E ^f   Zalmai, A ^g   Haanaes O C ^h   Dahl, T ⁱ   Knutsen, K ^j   Platou, C ^k   Gronvold T ^l   Vandvik, P O ^m   Haerem J ^l   Dorum H P ⁿ   von der Lippe, A ^o   Mangschau, A ^p  

^a UNIVERSITY OF OSLO   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c HAUGESUND HOSPITAL   (Norway)

^d lesund Hospital   (Norway)

^e NORDLAND HOSPITAL   (Norway)

^f NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^g LOVISENBERG DIAKONALE HOSPITAL   (Norway)

^h Tynset Hospital   (Norway)

ⁱ AKER UNIVERSITY HOSPITAL   (Norway)

^j VESTFOLD HOSPITAL TRUST   (Norway)

^k Innherred Hospital   (Norway)

^l Hedmark Central Hospital   (Norway)

^m Oppland Central Hospital   (Norway)

ⁿ Oppland County   (Norway)

^o DIAKONHJEMMET HOSPITAL   (Norway)

^p ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Acute myocardial infarction; Age; Drug indications; Mortality; Pharmacotherapy; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE;

ACUTE HEART INFARCTION; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG INDICATION; DRUG USE; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; SECONDARY PREVENTION; SURVIVAL RATE;

EID: 33646031175     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1172     Document Type: Article

References (16)

1. MRC/BHF. Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
2. Shepherd J, Blauw GJ, Murphy MB, et al., on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002; 360: 1623-1630.
3. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
4. (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
5. Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
7. Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
8. Walley T, Folino-Gallo P, Schwabe U, et al. Variations and increase in use of statins across Europe: Data from administrative databases. Br Med J 2004; 328: 385-386.
9. Reikvam A, Kvan E, Aursnes I. Use of cardiovascular drugs after acute myocardial infarction: A marked shift towards evidence-based drug therapy. Cardiovasc Drugs Ther 2002; 16: 451-456.
10. Kvan E, Reikvam A. Thrombolytic treatment in diabetic patients with acute myocardial infarction: Lower rates of use than in non-diabetic patients are explained by differences in presenting ECGs. Heart 2004; 90: 1346-1347.
11. DeWilde S, Carey IM, Bremner SA, et al. Evolution of statin prescribing 1994-2001: A case of agism but not of sexism? Heart 2003; 89: 417-421.
12. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001; 134: 931-940.
13. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987; 257: 2176-2180.
14. Clarke R, Lewington L, Youngman P, et al. Underestimation of the importance of blood pressure and cholesterol for coronary heart disease mortality in old age. Eur Heart J 2002; 23: 286-293.
15. Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol 1996; 77: 864-866.
16. http://www.lmi.no/digimaker/documents/TF_2003_j1PTh2177203.pdf. [Accessed 10 April 2004].